Publications by authors named "A Kleinheinz"
Article Synopsis
- Long-term effectiveness and safety of omalizumab for Chronic Inducible Urticaria (CIndU) were evaluated in a large cohort across 14 specialized centers, revealing it to be highly effective for most patients.
- Out of 234 patients, 73% reported significant improvements while the median treatment duration exceeded 5 years, mainly due to disease control.
- Patient age was a predictor of treatment continuation, with older patients less likely to discontinue due to well-controlled disease, and CIndU subtype did not impact treatment response or duration.
Importance: Treating patients with chronic urticaria using omalizumab has been shown to be safe and effective in randomized clinical trials. Multinational studies on long-term omalizumab performance in chronic urticaria in clinical practice settings are lacking, especially on drug survival. Drug survival, which refers to the length of time that patients are treated with a specific drug, is a comprehensive outcome covering effectiveness, safety, and patient and physician preferences.
View Article and Find Full Text PDF